MAP Kinase Regualtion of Cardiac Nuclear Receptors

心脏核受体的 MAP 激酶调节

• 批准号: 6855186
• 负责人: PHILIP M BARGER
• 金额: $ 30.1万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6855186
• 关键词: bioenergetics; cardiac myocytes; cellular respiration; enzyme activity; fatty acid metabolism; gel mobility shift assay; genetic regulation; heart metabolism; immunoprecipitation; laboratory rat; mitogen activated protein kinase; newborn animals; nuclear receptors; peroxisome proliferator activated receptor; proteomics; tissue /cell culture; transcription factor; yeast two hybrid system

DESCRIPTION (provided by applicant): Cardiac hypertrophy and heart failure are major causes of morbidity and mortality worldwide. These syndromes result from a variety of hemodynamic and humoral pathophysiologic stimuli, including hypertension, ischemia, and myocardial infarction. At the cellular level, protein kinase signaling cascades transduce extracellular signals into characteristic molecular and structural changes in the cardiac myocyte, which frequently includes alterations in normal energy production via dysregulation of mitochondrial fatty acid ¿-oxidation (FAO). The principal transcriptional regulator of FAO enzyme genes in heart, the peroxisome proliferator-activated receptor a (PPARa), has been shown to be deactivated by an extracellular signal-regulated kinase (ERK)-dependent process during cardiac hypertrophy, contributing to decreased FAO enzyme expression and loss of fatty acid oxidative capacity. Conversely, p38 mitogen activated protein kinase (MAPK) activation increases PPARa transcriptional activity via a direct phosphorylation event and enhances FAO in cardiac myocytes. This proposal is designed to understand the mechanisms whereby MAPK pathways differentially regulate the activity of PPARa in response to cellular stressors in the heart. This will be accomplished by i) identification of specific p38 MAPK phosphorylation sites on PPARa utilizing EMSA, ligand-binding assays, and protein-protein interaction assays; ii) determination of the mechanism by which ERK MAPK deactivates PPARa via in vivo phosphorylation studies, EMSA, ligand-binding assays, protein-protein interaction assays, co-immunoprecipitation assays in myocytes, and cotransfection assays with candidate repressors of PPARa activity; iii) definition of pathway specific regulation of PPARa target gene expression in vitro and in vivo and elucidation of the consequences of non-selective MAPK activation on PPARa activity; iv) identification of novel cardiac-expressed PPARa-interacting proteins via yeast two-hybrid and proteomics approaches. Modulation of the PPARa gene regulatory pathway by MAPK family members offers the potential to understand fundamental mechanisms whereby multiple signaling pathways integrate on a single transcription factor. We speculate that regulation of PPARa signaling is an integral component of the cellular stress response with implications for downstream modulation of cellular energy metabolism.

描述(申请人提供)：心脏肥大和心力衰竭是全球发病率和死亡率的主要原因。这些综合征是由各种血液动力学和体液病理生理刺激引起的，包括高血压、缺血和心肌梗死。在细胞水平上，蛋白激酶信号级联将细胞外信号转化为心肌细胞特有的分子和结构变化，这通常包括通过对线粒体脂肪酸氧化(FAO)的失调来改变正常的能量生产。心脏中FAO酶基因的主要转录调节因子--过氧化物酶体增殖物激活受体a(PPARa)被证明在心肌肥厚过程中被依赖于细胞外信号调节激酶(ERK)的过程失活，从而导致FAO酶表达减少和脂肪酸氧化能力丧失。相反，p38丝裂原活化蛋白激酶(MAPK)的激活通过直接磷酸化事件增加PPARa的转录活性，并增强心肌细胞中的FAO。这项建议旨在了解MAPK通路对心脏细胞应激源的PPARa活性进行差异性调节的机制。这将通过以下步骤完成：i)利用EMSA、配体结合分析和蛋白质-蛋白质相互作用分析鉴定PPARa上特定的p38 MAPK磷酸化位点；ii)通过体内磷酸化研究、EMSA、配体结合分析、蛋白质-蛋白质相互作用分析、蛋白质-蛋白质相互作用分析、心肌细胞免疫共沉淀分析，以及与PPARa活性候选阻滞剂共转染试验，确定ERK MAPK失活PPARa的机制；iii)定义PPARa目标基因在体外和体内表达的特异性调节途径，并阐明非选择性MAPK激活对PARPa活性的影响；iv)通过酵母双杂交和蛋白质组学方法鉴定新型心脏表达的PARPa相互作用蛋白。MAPK家族成员对PPARa基因调控途径的调控为理解多条信号通路整合到一个转录因子上的基本机制提供了可能。我们推测，PPARa信号的调节是细胞应激反应的一个组成部分，与细胞能量代谢的下游调节有关。